Invited Commentary.

In this article the author discusses her sentiments on a study about treatment of patients with multiple sclerosis (MS) with mitoxantrone. She says that the authors of this study have shown reasonably good response to the treatment in a significant number of patients. She emphasizes that mitoxantrone is not a standalone treatment modality in MS. She stresses that the study shows that there is a real need for a safe and affordable treatment.